Immunological tumor status may predict response to neoadjuvant chemotherapy and outcome after radical cystectomy in bladder cancer

Abstract Bladder cancer (BC) is the ninth most common cancer worldwide. Radical cystectomy (RC) with neoadjuvant chemotherapy (NAC) is recommended for muscle-invasive BC. The challenge of the neoadjuvant approach relates to challenges in selection of patients to chemotherapy that are likely to respo...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Minna Tervahartiala, Pekka Taimen, Tuomas Mirtti, Ilmari Koskinen, Thorsten Ecke, Sirpa Jalkanen, Peter J. Boström
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/21bdc6cc634a48d18cd99d7175ed9a8d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:21bdc6cc634a48d18cd99d7175ed9a8d
record_format	dspace
spelling	oai:doaj.org-article:21bdc6cc634a48d18cd99d7175ed9a8d2021-12-02T15:04:55ZImmunological tumor status may predict response to neoadjuvant chemotherapy and outcome after radical cystectomy in bladder cancer10.1038/s41598-017-12892-52045-2322https://doaj.org/article/21bdc6cc634a48d18cd99d7175ed9a8d2017-10-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-12892-5https://doaj.org/toc/2045-2322Abstract Bladder cancer (BC) is the ninth most common cancer worldwide. Radical cystectomy (RC) with neoadjuvant chemotherapy (NAC) is recommended for muscle-invasive BC. The challenge of the neoadjuvant approach relates to challenges in selection of patients to chemotherapy that are likely to respond to the treatment. To date, there are no validated molecular markers or baseline clinical characteristics to identify these patients. Different inflammatory markers, including tumor associated macrophages with their plastic pro-tumorigenic and anti-tumorigenic functions, have extensively been under interests as potential prognostic and predictive biomarkers in different cancer types. In this immunohistochemical study we evaluated the predictive roles of three immunological markers, CD68, MAC387, and CLEVER-1, in response to NAC and outcome of BC. 41% of the patients had a complete response (pT0N0) to NAC. Basic clinicopathological variables did not predict response to NAC. In contrast, MAC387+ cells and CLEVER-1+ macrophages associated with poor NAC response, while CLEVER-1+ vessels associated with more favourable response to NAC. Higher counts of CLEVER-1+ macrophages associated with poorer overall survival and CD68+ macrophages seem to have an independent prognostic value in BC patients treated with NAC. Our findings point out that CD68, MAC387, and CLEVER-1 may be useful prognostic and predictive markers in BC.Minna TervahartialaPekka TaimenTuomas MirttiIlmari KoskinenThorsten EckeSirpa JalkanenPeter J. BoströmNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-9 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Minna Tervahartiala Pekka Taimen Tuomas Mirtti Ilmari Koskinen Thorsten Ecke Sirpa Jalkanen Peter J. Boström Immunological tumor status may predict response to neoadjuvant chemotherapy and outcome after radical cystectomy in bladder cancer
description	Abstract Bladder cancer (BC) is the ninth most common cancer worldwide. Radical cystectomy (RC) with neoadjuvant chemotherapy (NAC) is recommended for muscle-invasive BC. The challenge of the neoadjuvant approach relates to challenges in selection of patients to chemotherapy that are likely to respond to the treatment. To date, there are no validated molecular markers or baseline clinical characteristics to identify these patients. Different inflammatory markers, including tumor associated macrophages with their plastic pro-tumorigenic and anti-tumorigenic functions, have extensively been under interests as potential prognostic and predictive biomarkers in different cancer types. In this immunohistochemical study we evaluated the predictive roles of three immunological markers, CD68, MAC387, and CLEVER-1, in response to NAC and outcome of BC. 41% of the patients had a complete response (pT0N0) to NAC. Basic clinicopathological variables did not predict response to NAC. In contrast, MAC387+ cells and CLEVER-1+ macrophages associated with poor NAC response, while CLEVER-1+ vessels associated with more favourable response to NAC. Higher counts of CLEVER-1+ macrophages associated with poorer overall survival and CD68+ macrophages seem to have an independent prognostic value in BC patients treated with NAC. Our findings point out that CD68, MAC387, and CLEVER-1 may be useful prognostic and predictive markers in BC.
format	article
author	Minna Tervahartiala Pekka Taimen Tuomas Mirtti Ilmari Koskinen Thorsten Ecke Sirpa Jalkanen Peter J. Boström
author_facet	Minna Tervahartiala Pekka Taimen Tuomas Mirtti Ilmari Koskinen Thorsten Ecke Sirpa Jalkanen Peter J. Boström
author_sort	Minna Tervahartiala
title	Immunological tumor status may predict response to neoadjuvant chemotherapy and outcome after radical cystectomy in bladder cancer
title_short	Immunological tumor status may predict response to neoadjuvant chemotherapy and outcome after radical cystectomy in bladder cancer
title_full	Immunological tumor status may predict response to neoadjuvant chemotherapy and outcome after radical cystectomy in bladder cancer
title_fullStr	Immunological tumor status may predict response to neoadjuvant chemotherapy and outcome after radical cystectomy in bladder cancer
title_full_unstemmed	Immunological tumor status may predict response to neoadjuvant chemotherapy and outcome after radical cystectomy in bladder cancer
title_sort	immunological tumor status may predict response to neoadjuvant chemotherapy and outcome after radical cystectomy in bladder cancer
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/21bdc6cc634a48d18cd99d7175ed9a8d
work_keys_str_mv	AT minnatervahartiala immunologicaltumorstatusmaypredictresponsetoneoadjuvantchemotherapyandoutcomeafterradicalcystectomyinbladdercancer AT pekkataimen immunologicaltumorstatusmaypredictresponsetoneoadjuvantchemotherapyandoutcomeafterradicalcystectomyinbladdercancer AT tuomasmirtti immunologicaltumorstatusmaypredictresponsetoneoadjuvantchemotherapyandoutcomeafterradicalcystectomyinbladdercancer AT ilmarikoskinen immunologicaltumorstatusmaypredictresponsetoneoadjuvantchemotherapyandoutcomeafterradicalcystectomyinbladdercancer AT thorstenecke immunologicaltumorstatusmaypredictresponsetoneoadjuvantchemotherapyandoutcomeafterradicalcystectomyinbladdercancer AT sirpajalkanen immunologicaltumorstatusmaypredictresponsetoneoadjuvantchemotherapyandoutcomeafterradicalcystectomyinbladdercancer AT peterjbostrom immunologicaltumorstatusmaypredictresponsetoneoadjuvantchemotherapyandoutcomeafterradicalcystectomyinbladdercancer
_version_	1718389004114591744

Immunological tumor status may predict response to neoadjuvant chemotherapy and outcome after radical cystectomy in bladder cancer

Ejemplares similares